Table 2.
Patient no. | Age (years) | Histology | FIGO stage | CA-125 | Neurological findings | Yo index |
---|---|---|---|---|---|---|
1 | 49 | Serous cystadenocarcinoma | IV | 730 | PCD | 659 |
2 | 69 | Serous cystadenocarcinoma | IV | 348 | PCD | 479 |
3 | 64 | Granulosa cell | I | 50 | None | 232 |
4 | 67 | Mucinous cystadenocarcinoma | I | 5 | None | 342 |
5 | 68 | Serous cystadenocarcinoma | I | 427 | None | 229 |
6 | 55 | Undifferentiated carcinoma | III | 28 | None | 663 |
7 | 83 | Mixed adenocarcinoma | III | 2100 | None | 457 |
8 | 84 | Mixed adenocarcinoma | III | 69 | None | 131 |
9 | 78 | Endometroid adenocarcinoma | III | 461 | Chemotherapy-induced neuropathy | 161 |
10 | 53 | Mucinous/Borderline | III | 6 | None | 201 |
11 | 58 | Serous cystadenocarcinoma | IV | 156 | None | 402 |
12 | 54 | Clear cell carcinoma | I | 10 | Chemotherapy-induced neuropathy | 195 |
13 | 62 | Endometroid adenocarcinoma | III | 250 | None | 319 |
Patients 1–8, Ovary group I; patients 9–13, Ovary group II; Patients 5 and 10 were treated by surgery alone, the others had adjuvant chemotherapy. Yo antibodies were detected in pre-operative serum or EDTA blood samples in all patients, except for patients 4, 7 and 8, in whom the samples were drawn after surgery. Borderline = adenocarcinoma with atypia. FIGO = international federation of gynaecology and obstetrics.